Engrail is a clinical-stage biotechnology company focused on building a portfolio of precision therapies for neuropsychiatric and neurodevelopmental disorders. Despite the enormous global burden of conditions such as anxiety, depression, and PTSD, many existing treatments lack sufficient efficacy or tolerability.
Engrail combines precision chemistry with deep pharmacology expertise to develop targeted medicines designed to address the biological drivers of these disorders. Its pipeline includes ENX-102, a next-generation GABA-modulating therapy currently in Phase 2 development for generalized anxiety disorder, and ENX-104, a dopamine receptor–targeting therapy in Phase 1 development for major depressive disorder associated with anhedonia.
The company is also advancing additional programs targeting mood, anxiety, and stress-related disorders, as well as rare neurological conditions, where novel mechanisms may offer breakthrough therapeutic potential.
